The metabolic microenvironment of melanomas: Prognostic value of MCT1 and MCT4

References

• Gatenby RA, Gillies RJ. Why do cancers have high aerobic glycolysis? Nat Rev Cancer 2004; 4:891-9; PMID:15516961; http://dx.doi.org/10.1038/nrc1478
   PubMed Web of Science ®Google Scholar
• Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 2011; 144:646-74; PMID:21376230; http://dx.doi.org/10.1016/j.cell.2011.02.013
   PubMed Web of Science ®Google Scholar
• Granja S, Pinheiro C, Reis RM, Martinho O, Baltazar F. Glucose addiction in cancer therapy: advances and drawbacks. Curr Drug Metab 2015; In press; PMID:26504932
   PubMed Web of Science ®Google Scholar
• Chiche J, Brahimi-Horn MC, Pouyssegur J. Tumour hypoxia induces a metabolic shift causing acidosis: a common feature in cancer. J Cell Mol Med 2010; 14:771-94; PMID:20015196; http://dx.doi.org/10.1111/j.1582-4934.2009.00994.x
   PubMed Web of Science ®Google Scholar
• Hirschhaeuser F, Sattler UG, Mueller-Klieser W. Lactate: a metabolic key player in cancer. Cancer Res 2011; 71:6921-5; PMID:22084445; http://dx.doi.org/10.1158/0008-5472.CAN-11-1457
   PubMed Web of Science ®Google Scholar
• Baltazar F, Pinheiro C, Morais-Santos F, Azevedo-Silva J, Queiros O, Preto A, Casal M. Monocarboxylate transporters as targets and mediators in cancer therapy response. Histol Histopathol 2014; 29:1511-24; PMID:24921258;
   PubMed Web of Science ®Google Scholar
• Erdmann F, Lortet-Tieulent J, Schuz J, Zeeb H, Greinert R, Breitbart EW, Bray F. International trends in the incidence of malignant melanoma 1953-2008–are recent generations at higher or lower risk? Int J Cancer 2013; 132:385-400; PMID:22532371; http://dx.doi.org/10.1002/ijc.27616
   PubMed Web of Science ®Google Scholar
• Niezgoda A, Niezgoda P, Czajkowski R. Novel Approaches to Treatment of Advanced Melanoma: A Review on Targeted Therapy and Immunotherapy. Biomed Res Int 2015; 2015:851387; PMID:26171394; http://dx.doi.org/10.1155/2015/851387
   PubMed Web of Science ®Google Scholar
• Safaee Ardekani G, Jafarnejad SM, Tan L, Saeedi A, Li G. The prognostic value of BRAF mutation in colorectal cancer and melanoma: a systematic review and meta-analysis. PLoS One 2012; 7:e47054; PMID:23056577; http://dx.doi.org/10.1371/journal.pone.0047054
   PubMed Web of Science ®Google Scholar
• Holderfield M, Deuker MM, McCormick F, McMahon M. Targeting RAF kinases for cancer therapy: BRAF-mutated melanoma and beyond. Nat Rev Cancer 2014; 14:455-67; PMID:24957944; http://dx.doi.org/10.1038/nrc3760
   PubMed Web of Science ®Google Scholar
• Ugurel S, Thirumaran RK, Bloethner S, Gast A, Sucker A, Mueller-Berghaus J, Rittgen W, Hemminki K, Becker JC, Kumar R, et al. B-RAF and N-RAS mutations are preserved during short time in vitro propagation and differentially impact prognosis. PLoS One 2007; 2:e236; PMID:17311103; http://dx.doi.org/10.1371/journal.pone.0000236
   PubMed Web of Science ®Google Scholar
• Bloom KJ, Vallera DU, Rueschoff J, Schilling R, Barbara Kovach Ba AS, Ochoa P, Langland R, Halait H, Dugan MC. Multisite analytic performance studies of a real-time polymerase chain reaction assay for the detection of BRAF V600E mutations in formalin-fixed, paraffin-embedded tissue specimens of malignant melanoma. Arch Pathol Lab Med 2012; 136:1385; PMID:22332713; http://dx.doi.org/10.5858/arpa.2011-0505-OA
   PubMed Web of Science ®Google Scholar
• Goydos JS, Mann B, Kim HJ, Gabriel EM, Alsina J, Germino FJ, Shih W, Gorski DH. Detection of B-RAF and N-RAS mutations in human melanoma. J Am Coll Surg 2005; 200:362-70; PMID:15737846; http://dx.doi.org/10.1016/j.jamcollsurg.2004.10.032
   PubMed Web of Science ®Google Scholar
• van Elsas A, Zerp SF, van der Flier S, Kruse KM, Aarnoudse C, Hayward NK, Ruiter DJ, Schrier PI. Relevance of ultraviolet-induced N-ras oncogene point mutations in development of primary human cutaneous melanoma. Am J Pathol 1996; 149:883-93; PMID:8780392
   PubMed Web of Science ®Google Scholar
• Chapman PB, Hauschild A, Robert C, Haanen JB, Ascierto P, Larkin J, Dummer R, Garbe C, Testori A, Maio M, et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 2011; 364:2507-16; PMID:21639808; http://dx.doi.org/10.1056/NEJMoa1103782
   PubMed Web of Science ®Google Scholar
• Sosman JA, Kim KB, Schuchter L, Gonzalez R, Pavlick AC, Weber JS, McArthur GA, Hutson TE, Moschos SJ, Flaherty KT, et al. Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib. N Engl J Med 2012; 366:707-14; PMID:22356324; http://dx.doi.org/10.1056/NEJMoa1112302
   PubMed Web of Science ®Google Scholar
• Flaherty KT, Robert C, Hersey P, Nathan P, Garbe C, Milhem M, Demidov LV, Hassel JC, Rutkowski P, Mohr P, et al. Improved survival with MEK inhibition in BRAF-mutated melanoma. N Engl J Med 2012; 367:107-14; PMID:22663011; http://dx.doi.org/10.1056/NEJMoa1203421
   PubMed Web of Science ®Google Scholar
• Flaherty KT, Infante JR, Daud A, Gonzalez R, Kefford RF, Sosman J, Hamid O, Schuchter L, Cebon J, Ibrahim N, et al. Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations. N Engl J Med 2012; 367:1694-703; PMID:23020132; http://dx.doi.org/10.1056/NEJMoa1210093
   PubMed Web of Science ®Google Scholar
• Hall A, Meyle KD, Lange MK, Klima M, Sanderhoff M, Dahl C, Abildgaard C, Thorup K, Moghimi SM, Jensen PB, et al. Dysfunctional oxidative phosphorylation makes malignant melanoma cells addicted to glycolysis driven by the (V600E)BRAF oncogene. Oncotarget 2013; 4:584-99; PMID:23603840; http://dx.doi.org/10.18632/oncotarget.965
   PubMed Web of Science ®Google Scholar
• Zerilli M, Zito G, Martorana A, Pitrone M, Cabibi D, Cappello F, Giordano C, Rodolico V. BRAF(V600E) mutation influences hypoxia-inducible factor-1alpha expression levels in papillary thyroid cancer. Mod Pathol 2010; 23:1052-60; PMID:20473281; http://dx.doi.org/10.1038/modpathol.2010.86
   PubMed Web of Science ®Google Scholar
• Kumar SM, Yu H, Edwards R, Chen L, Kazianis S, Brafford P, Acs G, Herlyn M, Xu X. Mutant V600E BRAF increases hypoxia inducible factor-1alpha expression in melanoma. Cancer Res 2007; 67:3177-84; PMID:17409425; http://dx.doi.org/10.1158/0008-5472.CAN-06-3312
   PubMed Web of Science ®Google Scholar
• Kroemer G, Pouyssegur J. Tumor cell metabolism: cancer's Achilles' heel. Cancer Cell 2008; 13:472-82; PMID:18538731; http://dx.doi.org/10.1016/j.ccr.2008.05.005
   PubMed Web of Science ®Google Scholar
• Yun J, Rago C, Cheong I, Pagliarini R, Angenendt P, Rajagopalan H, Schmidt K, Willson JK, Markowitz S, Zhou S, et al. Glucose deprivation contributes to the development of KRAS pathway mutations in tumor cells. Science 2009; 325:1555-9; PMID:19661383; http://dx.doi.org/10.1126/science.1174229
   PubMed Web of Science ®Google Scholar
• Gaglio D, Metallo CM, Gameiro PA, Hiller K, Danna LS, Balestrieri C, Alberghina L, Stephanopoulos G, Chiaradonna F. Oncogenic K-Ras decouples glucose and glutamine metabolism to support cancer cell growth. Mol Syst Biol 2011; 7:523; PMID:21847114; http://dx.doi.org/10.1038/msb.2011.56
   PubMed Web of Science ®Google Scholar
• Chiaradonna F, Sacco E, Manzoni R, Giorgio M, Vanoni M, Alberghina L. Ras-dependent carbon metabolism and transformation in mouse fibroblasts. Oncogene 2006; 25:5391-404; PMID:16607279; http://dx.doi.org/10.1038/sj.onc.1209528
   PubMed Web of Science ®Google Scholar
• Ying H, Kimmelman AC, Lyssiotis CA, Hua S, Chu GC, Fletcher-Sananikone E, Locasale JW, Son J, Zhang H, Coloff JL, et al. Oncogenic Kras maintains pancreatic tumors through regulation of anabolic glucose metabolism. Cell 2012; 149:656-70; PMID:22541435; http://dx.doi.org/10.1016/j.cell.2012.01.058
   PubMed Web of Science ®Google Scholar
• Scott DA, Richardson AD, Filipp FV, Knutzen CA, Chiang GG, Ronai ZA, Osterman AL, Smith JW. Comparative metabolic flux profiling of melanoma cell lines: beyond the Warburg effect. J Biol Chem 2011; 286:42626-34; PMID:21998308; http://dx.doi.org/10.1074/jbc.M111.282046
   PubMed Web of Science ®Google Scholar
• Ho J, de Moura MB, Lin Y, Vincent G, Thorne S, Duncan LM, Hui-Min L, Kirkwood JM, Becker D, Van Houten B, et al. Importance of glycolysis and oxidative phosphorylation in advanced melanoma. Mol Cancer 2012; 11:76; PMID:23043612; http://dx.doi.org/10.1186/1476-4598-11-76
   PubMed Web of Science ®Google Scholar
• Bettum IJ, Gorad SS, Barkovskaya A, Pettersen S, Moestue SA, Vasiliauskaite K, Tenstad E, Oyjord T, Risa O, Nygaard V, et al. Metabolic reprogramming supports the invasive phenotype in malignant melanoma. Cancer Lett 2015; 366:71-83; PMID:26095603; http://dx.doi.org/10.1016/j.canlet.2015.06.006
   PubMed Web of Science ®Google Scholar
• Hersey P, Watts RN, Zhang XD, Hackett J. Metabolic approaches to treatment of melanoma. Clin Cancer Res 2009; 15:6490-4; PMID:19861452; http://dx.doi.org/10.1158/1078-0432.CCR-09-0251
   PubMed Web of Science ®Google Scholar
• Smith LK, Rao AD, McArthur GA. Targeting metabolic reprogramming as a potential therapeutic strategy in melanoma. Pharmacol Res 2016; 107:42-7; PMID:26924126; http://dx.doi.org/10.1016/j.phrs.2016.02.009
   PubMedGoogle Scholar
• Zhang W. BRAF inhibitors: the current and the future. Curr Opin Pharmacol 2015; 23:68-73; PMID:26072431; http://dx.doi.org/10.1016/j.coph.2015.05.015
   PubMed Web of Science ®Google Scholar
• Carvalho KC, Cunha IW, Rocha RM, Ayala FR, Cajaiba MM, Begnami MD, Vilela RS, Paiva GR, Andrade RG, Soares FA. GLUT1 expression in malignant tumors and its use as an immunodiagnostic marker. Clinics (Sao Paulo) 2011; 66:965-72; PMID:21808860; http://dx.doi.org/10.1590/S1807-59322011000600008
   PubMed Web of Science ®Google Scholar
• Baer SC, Casaubon L, Younes M. Expression of the human erythrocyte glucose transporter Glut1 in cutaneous neoplasia. J Am Acad Dermatol 1997; 37:575-7; PMID:9344196; http://dx.doi.org/10.1016/S0190-9622(97)70174-9
   PubMed Web of Science ®Google Scholar
• Koch A, Arke Lang S, Johannes Wild P, Gantner S, Mahli A, Spanier G, Berneburg M, Muller M, Katrin Bosserhoff A, Hellerbrand C. Glucose transporter isoform 1 expression enhances metastasis of malignant melanoma cells. Oncotarget 2015; 6:32748-60; PMID:26293674
   PubMed Web of Science ®Google Scholar
• Syrjanen L, Luukkaala T, Leppilampi M, Kallioinen M, Pastorekova S, Pastorek J, Waheed A, Sly WS, Parkkila S, Karttunen T. Expression of cancer-related carbonic anhydrases IX and XII in normal skin and skin neoplasms. APMIS 2014; 122:880-9; PMID:24698175; http://dx.doi.org/10.1111/apm.12251
   PubMed Web of Science ®Google Scholar
• Smallbone K, Gavaghan DJ, Gatenby RA, Maini PK. The role of acidity in solid tumour growth and invasion. J Theor Biol 2005; 235:476-84; PMID:15935166; http://dx.doi.org/10.1016/j.jtbi.2005.02.001
   PubMed Web of Science ®Google Scholar
• Wykoff CC, Beasley NJ, Watson PH, Turner KJ, Pastorek J, Sibtain A, Wilson GD, Turley H, Talks KL, Maxwell PH, et al. Hypoxia-inducible expression of tumor-associated carbonic anhydrases. Cancer Res 2000; 60:7075-83; PMID:11156414
   PubMed Web of Science ®Google Scholar
• Shin HJ, Rho SB, Jung DC, Han IO, Oh ES, Kim JY. Carbonic anhydrase IX (CA9) modulates tumor-associated cell migration and invasion. J Cell Sci 2011; 124:1077-87; PMID:21363891; http://dx.doi.org/10.1242/jcs.072207
   PubMed Web of Science ®Google Scholar
• Chiche J, Ilc K, Brahimi-Horn MC, Pouyssegur J. Membrane-bound carbonic anhydrases are key pH regulators controlling tumor growth and cell migration. Adv Enzyme Regul 2010; 50:20-33; PMID:19895836; http://dx.doi.org/10.1016/j.advenzreg.2009.10.005
   PubMedGoogle Scholar
• Macheda ML, Rogers S, Best JD. Molecular and cellular regulation of glucose transporter (GLUT) proteins in cancer. J Cell Physiol 2005; 202:654-62; PMID:15389572; http://dx.doi.org/10.1002/jcp.20166
   PubMed Web of Science ®Google Scholar
• Ullah MS, Davies AJ, Halestrap AP. The plasma membrane lactate transporter MCT4, but not MCT1, is up-regulated by hypoxia through a HIF-1alpha-dependent mechanism. J Biol Chem 2006; 281:9030-7; PMID:16452478; http://dx.doi.org/10.1074/jbc.M511397200
   PubMed Web of Science ®Google Scholar
• Tennant DA, Duran RV, Gottlieb E. Targeting metabolic transformation for cancer therapy. Nat Rev Cancer 2010; 10:267-77; PMID:20300106; http://dx.doi.org/10.1038/nrc2817
   PubMed Web of Science ®Google Scholar
• Wahl ML, Owen JA, Burd R, Herlands RA, Nogami SS, Rodeck U, Berd D, Leeper DB, Owen CS. Regulation of intracellular pH in human melanoma: potential therapeutic implications. Mol Cancer Ther 2002; 1:617-28; PMID:12479222
   PubMed Web of Science ®Google Scholar
• Ganapathy V, Thangaraju M, Prasad PD. Nutrient transporters in cancer: relevance to Warburg hypothesis and beyond. Pharmacol Ther 2009; 121:29-40; PMID:18992769; http://dx.doi.org/10.1016/j.pharmthera.2008.09.005
   PubMed Web of Science ®Google Scholar
• Yamane LS, Scapulatempo-Neto C, Alvarenga L, Oliveira CZ, Berardinelli GN, Almodova E, Cunha TR, Fava G, Colaiacovo W, Melani A, et al. KRAS and BRAF mutations and MSI status in precursor lesions of colorectal cancer detected by colonoscopy. Oncol Rep 2014; 32:1419-26; PMID:25050586
   PubMed Web of Science ®Google Scholar
• de Lima Vazquez V, Vicente AL, Carloni A, Berardinelli G, Soares P, Scapulatempo C, Martinho O, Reis RM. Molecular profiling, including TERT promoter mutations, of acral lentiginous melanomas. Melanoma Res 2016; 26:93-9; PMID:26709572; http://dx.doi.org/10.1097/CMR.0000000000000222
   PubMed Web of Science ®Google Scholar
• Martinho O, Gouveia A, Viana-Pereira M, Silva P, Pimenta A, Reis RM, Lopes JM. Low frequency of MAP kinase pathway alterations in KIT and PDGFRA wild-type GISTs. Histopathology 2009; 55:53-62; PMID:19614767; http://dx.doi.org/10.1111/j.1365-2559.2009.03323.x
   PubMed Web of Science ®Google Scholar
• Pinheiro C, Longatto-Filho A, Scapulatempo C, Ferreira L, Martins S, Pellerin L, Rodrigues M, Alves VA, Schmitt F, Baltazar F. Increased expression of monocarboxylate transporters 1, 2, and 4 in colorectal carcinomas. Virchows Arch 2008; 452:139-46; PMID:18188595; http://dx.doi.org/10.1007/s00428-007-0558-5
   PubMed Web of Science ®Google Scholar
• Pinheiro C, Sousa B, Albergaria A, Paredes J, Dufloth R, Vieira D, Schmitt F, Baltazar F. GLUT1 and CAIX expression profiles in breast cancer correlate with adverse prognostic factors and MCT1 overexpression. Histol Histopathol 2011; 26:1279-86; PMID:21870331
   PubMed Web of Science ®Google Scholar
• Queiros O, Preto A, Pacheco A, Pinheiro C, Azevedo-Silva J, Moreira R, Pedro M, Ko YH, Pedersen PL, Baltazar F, et al. Butyrate activates the monocarboxylate transporter MCT4 expression in breast cancer cells and enhances the antitumor activity of 3-bromopyruvate. J Bioenerg Biomembr 2012; 44:141-53; PMID:22350013; http://dx.doi.org/10.1007/s10863-012-9418-3
   PubMed Web of Science ®Google Scholar
• Pinheiro C, Reis RM, Ricardo S, Longatto-Filho A, Schmitt F, Baltazar F. Expression of monocarboxylate transporters 1, 2, and 4 in human tumours and their association with CD147 and CD44. J Biomed Biotechnol 2010; 2010:427694; PMID:20454640; http://dx.doi.org/10.1155/2010/427694
   PubMed Web of Science ®Google Scholar
• Morais-Santos F, Granja S, Miranda-Gonçalves V, Moreira AHJ, Queirós S, Vilaça Jl, Schmitt FC, Longatto-Filho A, Paredes J, Baltazar F, et al. Targeting lactate transport suppresses in vivo breast tumour growth. Oncotarget 2015; PMID:26203664
   PubMed Web of Science ®Google Scholar
• Sousa B, Ribeiro AS, Nobre AR, Lopes N, Martins D, Pinheiro C, Vieira AF, Albergaria A, Gerhard R, Schmitt F, et al. The basal epithelial marker P-cadherin associates with breast cancer cell populations harboring a glycolytic and acid-resistant phenotype. BMC Cancer 2014; 14:734; PMID:25269858; http://dx.doi.org/10.1186/1471-2407-14-734
   PubMed Web of Science ®Google Scholar